Back in the new year to showcase their progress and forecast their goals at our January 2021 Psychedelic Capital event was Mindset Pharma. Their CEO, James Lanthier, and Chief Scientific Officer, Joseph Araujo, discussed how the Mindset Pharma team is helping reshape the current paradigm in the treatment of neuropsychiatric and neurodegenerative disorders. Here are three key takeaways from their January 2021 Psychedelic Capital presentation.
Key Takeaway #1: Mindset Pharma is Actively Developing the Next Generation of Psychedelic Drugs
While the ritualistic and medicinal use of psychedelic plants and fungi, such as psilocybin, may be centuries old, the Mindset Pharma team is breathing new life into them by enhancing them through modern technology. Through advanced biotechnology and chemical synthesis techniques, the Mindset Pharma team is actively improving the classic psychedelic compounds to reduce toxicity and adverse effects, while increasing their efficacy. Not only does this allow for a new generation of psychedelic-inspired compounds with maximum efficacy, but it also creates the opportunity for patentable drugs and novel IP. Indeed, the classic psychedelics, such as psilocybin, cannot be patented as they are in the public domain. Thus, by enhancing the current compounds through advanced biotechnological and synthetic methods, Mindset is simultaneously creating a new generation of psychedelic drugs with greater efficacy that are also patentable.
Key Takeaway #2: Mindset Pharma’s Unique Chemical Synthesis Program Will Allow for Large Scale GMP Psilocybin Production
Currently, gaining access to GMP (good manufacturing practices) psilocybin for research purposes is expensive and not straightforward. As demand for GMP psilocybin grows due to increased enthusiasm in the academic research space, companies like Mindset Pharma will have the opportunity to help meet this demand through developing novel and effective techniques to scale production. Indeed, the team at Mindset is currently working to develop an unique chemical synthesis program that will allow for just that–large scale GMP production. In addition to this, the Mindset Pharma team is also expanding their NCE (new chemical entity) program to enrich their library of psychedelic compounds. Indeed, by simply observing the pace of research surrounding psilocybin alone, it is clear that scalable GMP production will be crucial to the industry at large. Therefore, Mindset’s novel chemical synthesis program puts them at the forefront of psychedelic drug development.
Key Takeaway #3: The Mindset Pharma Team is Experienced & Open to Possibility
Perhaps one of the most important elements crafting new psychedelic medicines, outside of deep experience in pharmaceutical drug development, is the capacity to think outside the box and be open to unique possibilities. Indeed, this is a hallmark feature of the Mindset Pharma team, as expressed by their CEO and CSO during their January 2021 Psychedelic Capital presentation. They understand that drugs like psilocybin are incredibly diverse and versatile in the people it can help and the conditions it can treat. They eloquently expressed that it is still early days in understanding the neuropharmacology of these compounds and that there is plenty of room for growth. While the current focus is indeed to provide these medicines to those who need it most, the team at Mindset Pharma is ready for the future and willing to think big. This makes their experienced and dynamic team poised for success in this emerging space.
A Look Ahead for Mindset Pharma
The innovative team at Mindset Pharma returned to the main stage at the first Psychedelic Capital of 2021 to express their rapid growth and ambitious goals as a key player in the modern psychedelic renaissance. Their application of psychedelic medicinal chemistry to create a pipeline of enhanced, psychedelic inspired medication with reduced toxicity and increased efficacy puts them at a significant advantage in this emerging field. We are grateful to have had the Mindset Pharma team back on the Psychedelic Capital stage as they are certainly a company worth following throughout this historic renaissance.
The post PsyCap Recap: 3 Key Takeaways From the January 2021 Mindset Pharma Psychedelic Capital Presentation appeared first on Microdose Psychedelic Insights.
